PD-L1 is overexpressed in many tumor types to evade the immune attack and its expression generally (but not always) correlates with progression (Gato-Canas et al., 2017; Escors et al., 2018; Bocanegra et al., 2019; Kattan et al., 2019). This evidence concerns the gene CD274 and neoplasm.